Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 2(66), 2022

DOI: 10.1128/aac.02067-21

Links

Tools

Export citation

Search in Google Scholar

Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections

Journal article published in 2022 by Alba Ruedas-López, Isaac Alonso-García, Cristina Lasarte-Monterrubio, Paula Guijarro-Sánchez ORCID, Eva Gato, Juan Carlos Vázquez-Ucha ORCID, Juan Andrés Vallejo, Pablo Arturo Fraile-Ribot, Begoña Fernández-Pérez, David Velasco, José María Gutiérrez-Urbón, Marina Oviaño ORCID, Alejandro Beceiro ORCID, Concepción González-Bello ORCID, Antonio Oliver ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Infections caused by ceftolozane-tazobactam and ceftazidime-avibactam-resistant P. aeruginosa infections are an emerging concern. We aimed to analyze the underlying ceftolozane-tazobactam and ceftazidime-avibactam resistance mechanisms in all multidrug-resistant or extensively drug-resistant (MDR/XDR) P. aeruginosa isolates recovered during 1 year (2020) from patients with a documented P. aeruginosa infection.